Benzodiazepines Should Be Avoided in PTSD Due to Lack of Efficacy and Significant Harm
Benzodiazepines are relatively contraindicated in PTSD and should generally not be prescribed, as they are ineffective for core PTSD symptoms and are associated with worse outcomes, increased risk of developing PTSD after trauma, impaired psychotherapy response, and higher rates of substance use, aggression, and depression. 1, 2
Evidence Against Benzodiazepine Use
Lack of Efficacy
The evidence consistently demonstrates that benzodiazepines do not improve PTSD symptoms:
Prevention failure: When administered early after trauma (within 1 week), benzodiazepines were associated with a paradoxically higher rate of PTSD development - 63% of those receiving benzodiazepines met PTSD criteria at 6 months compared to only 23% receiving placebo 3
Treatment ineffectiveness: Systematic reviews and meta-analyses found benzodiazepines ineffective for treating core PTSD symptoms, with risks outweighing any potential short-term benefits 2, 4
Specific Harms in PTSD Populations
The 2024 VA/DoD Clinical Practice Guideline provides a strong recommendation against benzodiazepine use 1, based on evidence showing:
- Worse overall PTSD severity with benzodiazepine use 2
- Impaired psychotherapy outcomes - benzodiazepines interfere with the extinction learning that is central to trauma-focused therapies 2
- Increased aggression and depression 2
- Higher substance use risk in a population already vulnerable to addiction 2
- Significantly increased hospitalization risk when prescribed to veterans with PTSD 5
Additional Safety Concerns
Beyond PTSD-specific issues, benzodiazepines carry general risks that are particularly problematic in this population:
- Dangerous interactions: When co-prescribed with opioids (common in PTSD patients with chronic pain), benzodiazepines quadruple the risk of fatal overdose 6
- Withdrawal complications: Abrupt discontinuation can cause rebound anxiety, seizures, delirium tremens, and rarely death 6
- Cognitive impairment and dependence risk with long-term use 7
Clinical Algorithm
When a PTSD patient presents with anxiety or sleep disturbance:
First-line: Offer trauma-focused psychotherapy (prolonged exposure, cognitive processing therapy, or EMDR) 1
If pharmacotherapy needed: Prescribe SSRIs (sertraline or paroxetine) or venlafaxine - these have proven efficacy for PTSD 1, 8
For anxiety symptoms specifically: Use evidence-based psychotherapies (CBT) and/or antidepressants rather than benzodiazepines 6
If patient already on benzodiazepines: Taper gradually (25% dose reduction every 1-2 weeks) with CBT support to increase success rates 6
Common Pitfalls to Avoid
Don't prescribe benzodiazepines for "short-term relief" while waiting for psychotherapy or antidepressants to work - this can worsen long-term outcomes and interfere with subsequent trauma-focused therapy 2
Don't assume patient satisfaction equals efficacy - while patients may report subjective relief, objective outcomes are worse 3
Don't use benzodiazepines for acute stress reactions immediately post-trauma, as this may actually increase the risk of developing chronic PTSD 3
Rare Exceptions
The only scenario where brief, judicious benzodiazepine use might be considered is severe, acute insomnia causing significant functional impairment when other interventions have failed, but this should be time-limited (days, not weeks) and closely monitored 9. However, even in this context, alternative approaches (trazodone, mirtazapine, prazosin for nightmares) are preferable.
The updated German S3 guidelines explicitly state that benzodiazepines and Z-drugs should generally be avoided in PTSD 10, reinforcing the international consensus against their use in this population.